Intrahepatic aterial 90-yttrium resin spheres to treat liver cancer

Grady, Edgar D.

doi:10.1016/0047-0740(78)90150-x

Cited by 13 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In respect to metastatic spread to the liver, long-term survival is determined by the tumor biology and the propensity for extra-hepatic disease [3]. A recent advance in the treatment of these tumors is the use of selective internal radiation therapy (SIRT) with yttrium-90 (Y 90 ) microspheres, described as direct intratumoral injection, with transarteril administration in humans, first described as feasible, and then later with the ability to induce tumor necrosis and regression [4,5].…”

Section: Introductionmentioning

confidence: 99%

Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 Therapy

Whitney

Tatum

Hahl

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 Therapy

Whitney

Tatum

Hahl

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

“…Resin-based microspheres have a lower specific activity per particle and thus require more particles to achieve any given dose. Glass-based microspheres are routinely delivered as a complete dose with little embolic effect at a potentially greater dosage with larger parenchymal coverage (16,17). No direct comparison of the efficacy of the two microsphere products has been reported in the literature.…”

Section: Vehicles Delivering 90 Y: Resin and Glass Microspheresmentioning

confidence: 99%

⁹⁰Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery

Camacho¹,

Moncayo²,

Kokabi³

et al. 2015

RadioGraphics

View full text Add to dashboard Cite

Primary and metastatic liver cancers are responsible for considerable morbidity and mortality, and many patients are not curable at presentation. Therefore, new therapies such as radioembolization with yttrium 90 ((90)Y)-labeled microspheres are an alternative method to treat patients with unresectable primary or secondary liver tumors. Patient selection, treatment technique, and early recognition of potential complications are the keys for successful patient outcomes. The activity of administered (90)Y microspheres depends on multiple variables, including the tumor burden, the volume of the liver lobe to be treated, the type of (90)Y microspheres, and the hepatopulmonary shunt fraction. Preprocedural planning relies on the results of cross-sectional imaging to determine the extent of disease, tumoral and nontumoral liver volumes, patency of the portal vein, and the degree of extrahepatic disease. A multidisciplinary approach that combines expertise in cross-sectional imaging, nuclear medicine, and flow dynamics is critical to adequately target malignant tissue. Preprocedural multimodality imaging, particularly combined single photon emission computed tomography (SPECT) and computed tomography (CT) imaging (SPECT/CT), may be used to identify nontarget imaging patterns that, if recognized, can potentially be corrected with either branch vessel embolization or catheter repositioning. Postprocedural multimodality imaging is also useful to confirm the appropriate delivery of (90)Y microspheres, enabling early identification of potential complications and the adequacy of microsphere distribution, thereby optimizing planning for subsequent therapies.

show abstract

“…The use of 90 Y to treat these diseases began with its topical application and direct intratumoral injection. Transarterial administration of 90 Y-bearing microspheres in humans was described in the early literature as feasible (7)(8)(9), and, somewhat later, as capable of inducing tumor regression (10). The results of numerous subsequent studies have supported the use and confirmed the effectiveness of 90 Y-bearing microspheres in the treatment of hepatic primary neoplasms (11)(12)(13)(14)(15) and metastatic neoplasms (16 -18).…”

Section: Introductionmentioning

confidence: 99%

Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications

et al. 2005

View full text Add to dashboard Cite

Management of hepatic malignancies is a ubiquitous medical problem. Surgical resection of primary or metastatic liver cancer, with or without adjuvant chemotherapy, is the most effective method for enhancing survival; however, hepatic malignancies in the vast majority of patients are unresectable both at initial manifestation and at recurrence. In these patients, palliative cytoreductive therapies may help to retard tumor progression and therefore favorably alter the course of the disease. Since hepatic neoplasms are principally supplied by the hepatic artery, various arterially delivered cytotoxic agents have been developed to achieve these objectives. Recently, the Food and Drug Administration approved the transarterial administration of yttrium-90 microspheres for liver-directed therapy. Effective use of these devices requires knowledge of the accumulated clinical experience and a dedicated multidisciplinary effort to ensure optimal outcomes and avoid therapy-specific life-threatening complications.

show abstract

Intrahepatic aterial 90-yttrium resin spheres to treat liver cancer

Cited by 13 publications

References 1 publication

Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 Therapy

Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 Therapy

⁹⁰Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery

Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications

Contact Info

Product

Resources

About

Intrahepatic aterial 90-yttrium resin spheres to treat liver cancer

Cited by 13 publications

References 1 publication

Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 Therapy

Safety of Hepatic Resection in Metastatic Disease to the Liver After Yttrium-90 Therapy

90Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery

Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications

Contact Info

Product

Resources

About

⁹⁰Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery